ADMA Biologics, Inc. (ADMA) Reaches $5.04 After 7.00% Up Move; Cambian Group plc (LON:CMBN) Covered By 3 Bullish Analysts Last Week

June 17, 2018 - By Adrian Mccoy

ADMA Biologics, Inc. (NASDAQ:ADMA) Logo

The stock of ADMA Biologics, Inc. (NASDAQ:ADMA) is a huge mover today! The stock increased 3.28% or $0.16 during the last trading session, reaching $5.04. About 409,235 shares traded or 124.07% up from the average. ADMA Biologics, Inc. (NASDAQ:ADMA) has risen 49.86% since June 17, 2017 and is uptrending. It has outperformed by 37.29% the S&P500. Some Historical ADMA News: ; 22/04/2018 DJ ADMA Biologics Inc, Inst Holders, 1Q 2018 (ADMA); 14/05/2018 – ADMA Biologics: Biotest Will Waive, Terminate All Rights to Name a Director to ADMA’s Bd of Directors; 14/05/2018 – ADMA Biologics 1Q Loss/Shr 39c; 16/05/2018 – ADMA Biologics Granted U.S. Patent for Treating Respiratory Infections; 24/04/2018 – ADMA BIOLOGICS INC – COMPLETED MANUFACTURING, RELEASE AND HAS MADE COMMERCIAL SALES OF ITS FIRST BATCH OF NABI-HB; 14/05/2018 – ADMA BIOLOGICS – AT MARCH 31, 2018, ADMA HAD CASH AND CASH EQUIVALENTS OF $26.1 MLN, AS COMPARED TO $43.1 MLN AT DECEMBER 31, 2017; 14/05/2018 – ADMA BIOLOGICS INC – BPC WILL WAIVE AND TERMINATE ALL RIGHTS TO NAME A DIRECTOR AND OBSERVER TO ADMA’S BOARD OF DIRECTORS; 14/05/2018 – ADMA BIOLOGICS – ADMA WILL TERMINATE RIGHTS TO REPURCHASE 2 ADMA BIOCENTERS WHICH CO HAD PREVIOUSLY AGREED TO TRANSFER TO BPC ON JANUARY 1, 2019; 24/04/2018 – ADMA Biologics Announces the Release of its First Commercial Batch of Nabi-HB Manufactured Under its Ownership; 14/05/2018 – ADMA Biologics: Total Outstanding Common Stk Reduced by Approximately 19%The move comes after 7 months positive chart setup for the $227.28M company. It was reported on Jun, 17 by Barchart.com. We have $5.39 PT which if reached, will make NASDAQ:ADMA worth $15.91M more.

Among 7 analysts covering Cambian Group Plc (LON:CMBN), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Cambian Group Plc had 54 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was upgraded by Canaccord Genuity to “Speculative Buy” on Tuesday, May 24. The stock has “Buy” rating by Canaccord Genuity on Thursday, January 14. The firm earned “Neutral” rating on Tuesday, November 28 by JP Morgan. Investec downgraded the shares of CMBN in report on Friday, March 11 to “Hold” rating. JP Morgan maintained Cambian Group plc (LON:CMBN) rating on Wednesday, February 21. JP Morgan has “Neutral” rating and GBX 153 target. Numis Securities maintained it with “Buy” rating and GBX 380 target in Friday, September 4 report. Barclays Capital upgraded the stock to “Overweight” rating in Friday, September 11 report. The firm earned “Neutral” rating on Wednesday, January 4 by JP Morgan. The rating was maintained by Liberum Capital on Friday, October 20 with “Buy”. Canaccord Genuity maintained Cambian Group plc (LON:CMBN) rating on Wednesday, September 14. Canaccord Genuity has “Speculative Buy” rating and GBX 95 target. See Cambian Group plc (LON:CMBN) latest ratings:

21/03/2018 Broker: Liberum Capital Rating: Buy Old Target: GBX 238.00 New Target: GBX 238.00 Maintain
21/02/2018 Broker: JP Morgan Rating: Neutral Old Target: GBX 153.00 New Target: GBX 153.00 Maintain
13/02/2018 Broker: Liberum Capital Rating: Buy Old Target: GBX 232.00 New Target: GBX 238.00 Maintain

The stock decreased 0.51% or GBX 0.8 during the last trading session, reaching GBX 157.6. About 49,741 shares traded. Cambian Group plc (LON:CMBN) has 0.00% since June 17, 2017 and is . It has underperformed by 12.57% the S&P500.

Cambian Group plc, together with its subsidiaries, provides specialist educational and behavioral health services for children in the United Kingdom. The company has market cap of 290.30 million GBP. It offers services in the areas of autism and learning difficulties, specialist residential care and mental health, therapeutic fostering care and emotional support, deaf, and intellectual disabilities. It currently has negative earnings. The firm delivers its services through a network of 224 locations across England and Wales.

Investors sentiment decreased to 2.86 in 2018 Q1. Its down 0.14, from 3 in 2017Q4. It turned negative, as 1 investors sold ADMA Biologics, Inc. shares while 6 reduced holdings. 11 funds opened positions while 9 raised stakes. 15.52 million shares or 0.06% less from 15.53 million shares in 2017Q4 were reported. Northern Trust Corp stated it has 29,143 shares or 0% of all its holdings. Bank Of America De reported 5,188 shares. Broadfin Capital Ltd Llc reported 0.52% stake. Blackrock accumulated 40,536 shares. National Bank Of Mellon Corp invested in 0% or 19,037 shares. 683 Cap Ltd owns 805,000 shares. Highbridge Cap Management Limited Liability Co invested in 312,500 shares or 0.02% of the stock. Moreover, Millennium Management Ltd Liability Corp has 0% invested in ADMA Biologics, Inc. (NASDAQ:ADMA). Sigma Planning holds 18,730 shares. Moreover, Barclays Public Limited Company has 0% invested in ADMA Biologics, Inc. (NASDAQ:ADMA) for 2,901 shares. Prelude Cap stated it has 57,300 shares or 0.02% of all its holdings. Morgan Stanley stated it has 13,011 shares or 0% of all its holdings. Advisory Network Limited Liability Co owns 1,700 shares for 0% of their portfolio. Jpmorgan Chase accumulated 39,491 shares or 0% of the stock. Geode Cap Limited Liability Company reported 112,000 shares.

More notable recent ADMA Biologics, Inc. (NASDAQ:ADMA) news were published by: Seekingalpha.com which released: “ADMA Biologics: The Right Way To Fix Manufacturing” on June 14, 2018, also Nasdaq.com with their article: “ADMA Biologics Announces Closing of $40M Public Offering” published on June 12, 2018, Globenewswire.com published: “ADMA Biologics Announces Pricing of Public Offering of Common Stock” on June 08, 2018. More interesting news about ADMA Biologics, Inc. (NASDAQ:ADMA) were released by: Streetinsider.com and their article: “After-Hours Stock Movers 06/07: (ZUMZ) (DOCU) (SFIX) Higher; (MVIS) (ITI) (ADMA) Lower (more…)” published on June 07, 2018 as well as Seekingalpha.com‘s news article titled: “Rounds Report: Versartis Rallied Due To Strong Turnaround Progress” with publication date: June 15, 2018.

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, makes, and intends to commercialize specialty plasma biologics for the treatment and prevention of immune deficiencies and infectious diseases. The company has market cap of $227.28 million. The Company’s lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. It currently has negative earnings. The firm also operates source plasma collection facilities in Norcross and Marietta, Georgia.

Among 3 analysts covering ADMA Biologics (NASDAQ:ADMA), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ADMA Biologics had 9 analyst reports since September 9, 2015 according to SRatingsIntel. On Monday, August 1 the stock rating was downgraded by Maxim Group to “Hold”. The firm has “Buy” rating by Maxim Group given on Monday, January 23. The stock of ADMA Biologics, Inc. (NASDAQ:ADMA) earned “Buy” rating by Maxim Group on Thursday, September 17. Ladenburg maintained the shares of ADMA in report on Wednesday, June 13 with “Buy” rating. On Monday, August 1 the stock rating was downgraded by Raymond James to “Market Perform”. The firm has “Outperform” rating by Raymond James given on Tuesday, November 14. The stock of ADMA Biologics, Inc. (NASDAQ:ADMA) has “Buy” rating given on Wednesday, June 7 by Maxim Group. The stock of ADMA Biologics, Inc. (NASDAQ:ADMA) earned “Buy” rating by Maxim Group on Wednesday, June 28. The rating was initiated by Raymond James on Wednesday, September 9 with “Strong Buy”.

Analysts await ADMA Biologics, Inc. (NASDAQ:ADMA) to report earnings on August, 10. They expect $-0.35 EPS, up 36.36% or $0.20 from last year’s $-0.55 per share. After $-0.35 actual EPS reported by ADMA Biologics, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>